Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates

Area of Science:

• Antimicrobial resistance
• Drug discovery and development
• Medicinal chemistry

Background:

• Antibiotic resistance is a growing global health threat, driven by bacterial defense mechanisms.
• Traditional antibacterial drug discovery faces challenges in developing new effective agents.
• Hybrid antibiotic strategies offer a promising approach to overcome resistance.

Purpose of the Study:

• To explore the potential of antibiotic hybrid approaches in combating drug-resistant bacteria.
• To highlight novel chemical entities and therapeutic strategies developed through hybrid paradigms.
• To showcase advancements in antibacterial drug development utilizing multi-targeted and conjugated agents.

Main Methods:

• Development of hybrid chemotherapeutic agents with multiple mechanisms of action.
• Application of the antibiotic hybrid paradigm to macrocycles and conjugation strategies.
• Clinical evaluation of novel hybrid antibiotic candidates, including antibody-antibiotic conjugates.

Main Results:

• Hybrid antibiotics demonstrate potent activity against multi-drug resistant bacterial strains.
• Novel chemical entities, such as TD-1792 and TNP-2092, have advanced to clinical trials.
• Antibody-antibiotic conjugates like DSTA4637S show efficacy against persistent bacterial infections like *S. aureus* bacteremia.

Conclusions:

• Antibiotic hybrid approaches represent a rejuvenated and effective strategy in antibacterial drug discovery.
• Multi-targeted and conjugated antibiotics offer significant advantages in overcoming resistance.
• Novel hybrid therapies hold substantial promise for treating challenging bacterial infections and combating the rise of superbugs.